The FDA approval of Biogen’s Aduhelm for Alzheimer’s has breathed new life into neurology units across biopharma, none more so than nearest rival Eli Lilly. Looking to ride that building wave, Lilly is ready for a new look.
Lilly will break up its larger Bio-Medicines business, propping up new neuroscience and immunology units as part of a broad reorganization of the Indianapolis drugmaker’s pipeline centered, in part, around late-stage Alzheimer’s candidate donanemab, the company announced Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 114,600+ biopharma pros reading Endpoints daily — and it’s free.
